Table 3 –
Characteristics of 98 prostate cancer patients treated with radical prostatectomy but retrospectively evaluated as candidates for focal therapy with the more restrictive definition of extensive disease. All values are median (interquartile range) or frequency (proportion)
| No Extensive Disease at RP (N=81; 83%) | Extensive Disease at RP (N=17; 17%) | |
|---|---|---|
| Age at diagnostic biopsy (yr) | 58 (53, 63) | 58 (53, 65) |
| Gleason score at diagnostic biopsy | ||
| 6 | 54 (67%) | 2 (12%) |
| 3+4 | 27 (33%) | 15 (88%) |
| Percentage of positive cores at diagnostic biopsy | 15.4 (8.3, 25.0) | 16.7 (8.3, 33.3) |
| Clinical stage | ||
| T1c | 72 (89%) | 12 (71%) |
| T2a | 9 (11%) | 5 (29%) |
| Kattan nomogram score* | 9.8 (8.2, 15.4) | 18.0 (14.5, 20.9) |
| Prostate volume on MRI (cm3) | 35.0 (27.0, 44.9) | 29.0 (24.9, 36.0) |
| Pre-RP PSA level (ng/ml) | 4.7 (3.6, 6.5) | 5.0 (4.0, 7.6) |
| Gleason score at RP | ||
| 6 | 26 (32%) | 0 (0%) |
| 3+4 | 55 (68%) | 17 (100%) |
| Gleason pattern 4/5 in bilateral lobes | 18 (22%) | 9 (53%) |
| ≥0.5 mL Gleason pattern 4/5 in bilateral lobes | 0 | 2 (12%) |
| Pathologic stage at RP | ||
| T2 | 81 (100%) | 0 (0%) |
| T3a | 0 (0%) | 14 (82%) |
| T3b | 0 (0%) | 2 (12%) |
| T4 | 0 (0%) | 1 (5.9%) |
| Extraprostatic extension | 0 (0%) | 17 (100%) |
| Seminal vesicle involvement | 0 (0%) | 2 (12%) |
| Lymph node invasion | 0 (0%) | 1 (5.9%) |
MRI = magnetic resonance imaging; PSA = prostate-specific antigen; RP = radical prostatectomy.
*
The Kattan nomogram score incorporates PSA, clinical stage, and biopsy Gleason score.